Vertex Pharmaceuticals Incorporated - Common Stock · Transaction Mar 27, 2026 · Filed Jul 21, 2026 · $1,001 to $15,000
XNAS · VRTX
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Vertex Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
$556.75
Veridion Score
BETAHIGH CONF · 6 of 6 factors measuredWed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET · VRTX
MethodologyVRTX
Vertex Pharmaceuticals Inc
Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
67/ 100
Veridion Score
Upper range · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is VRTX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Vertex Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
1991
Employees
6K
Country
US
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$556.75
Last session
Day high
$556.75
Last session
Day low
$556.75
Last session
Previous close
$556.75
52W high
$556.75
0.00% from high
52W low
$376.62
100% of range
Market cap
$141.1B
P/E
33.70×
EPS
$16.52
Beta
0.18
Shares out
253.5M
Avg volume
1.2M
VWAP
$556.75
Last session
Price history computed in-house
1W
+1.68%
1M
+16.30%
3M
+24.60%
1Y
+40.37%
YTD
+22.81%
SMA 50 $505.79 · above
SMA 200 $464.98 · above
52W position 100%
VRTX overview
SEC industry peers
VRTX peers
Related filings and maps
Public disclosures
Congress activity in VRTX
Official filing ↗
David J. TaylorSell
VRTX · Transaction Jan 29, 2026 · Filed Feb 2, 2026 · $1,001 to $15,000
David J. TaylorSell
Vertex Pharmaceuticals Incorporated - Common Stock · Transaction Jan 29, 2026 · Filed Feb 2, 2026 · $1,001 to $15,000
VRTX · Transaction Aug 7, 2025 · Filed Sep 2, 2025 · $1,001 to $15,000
Vertex Pharmaceuticals Incorporated - Common Stock · Transaction Jun 11, 2025 · Filed Aug 13, 2025 · $1,001 to $15,000
Federal contracts
VRTX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for VRTX in this window.
Lobbying spend
VRTX lobbying filings, year to date.
Registered lobbying filings matched to Vertex Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for VRTX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for VRTX.
Options
Sovereign unlock shows live options positioning for VRTX.